向日葵拟收购兮璞材料100%股权及贝得药业40%股权 股票复牌

Core Viewpoint - The company plans to acquire 100% equity of Xipu Materials and 40% equity of Beid Pharmaceutical through a combination of share issuance and cash payment, aiming to enhance asset quality and long-term development [1] Group 1: Acquisition Details - The company will purchase 100% equity of Xipu Materials from six counterparties, which specializes in high-end semiconductor materials, including high-purity electronic special gases and silicon-based precursors [1] - The company will also acquire 40% equity of Beid Pharmaceutical, a subsidiary engaged in the research, manufacturing, and sales of various drugs [1] Group 2: Strategic Implications - This transaction is expected to improve the company's asset quality and promote long-term growth [1] - Post-transaction, the company will enter the high-end semiconductor materials sector, creating a second growth curve and accelerating the transition to new productive forces [1] - The move aims to generate new profit growth points, thereby enhancing the company's sustainable profitability [1]